#USA #Boston #microbiome #Seed Health #DS-01®

Seed Health Unveils Groundbreaking Clinical Trial Results on DS-01®

Overview

Seed Health, a pioneering company in microbiome science, presented new clinical trial data at the Digestive Disease Week (DDW) 2025, highlighting its flagship product, DS-01® Daily Synbiotic. This innovative synbiotic has shown the capability to significantly enhance the production of two vital microbial metabolites, Urolithin A and butyrate, both crucial for gut and overall health. The study underscores the potential these microbiome-targeted products have in influencing various biological systems, which could lead to advances in health management.

Key Findings

The randomized, placebo-controlled trial involved healthy adults and provided compelling evidence of DS-01®’s benefits. Here are the main findings from the study:

1. Increased Production of Urolithin A

The clinical trial demonstrated that DS-01® not only elevated the production of Urolithin A significantly, boosting urinary levels by approximately 100-fold within just seven days (P<0.0001), but this increase was also sustained over a 91-day period. By the end of the trial, all participants in the DS-01® group had become producers of Urolithin A, compared to only 44% in the placebo group (P<0.01).

2. Enhancements in Gut Microbiota

The trial also highlighted the synbiotic’s ability to increase the abundance of specific Lactobacillus species that are vital for converting dietary polyphenols into Urolithin A precursors (P<0.001).

3. Positive Impact on Butyrate Levels

Moreover, DS-01® was seen to elevate fecal butyrate levels significantly through Day 91 (P<0.03), particularly in individuals with initially low levels. Notably, the placebo group did not show any changes in butyrate levels, indicating the product's distinct efficacy.

4. Reduction in Inflammation Markers

The study also observed a marked reduction in C-Reactive Protein (CRP), a systemic marker for inflammation, suggesting that DS-01® may influence important immune pathways, with a significant decrease seen through Day 91 (P<0.02).

5. Increased Microbiome Diversity

Additionally, participants taking DS-01® exhibited significantly greater diversity in Bifidobacterium and Lactobacillus species at all measured time points compared to the placebo group, which is an encouraging sign for overall gut health (P<0.0001).

Clinical Implications

Dr. Zain Kassam, Chief Medical Officer at Seed Health, expressed enthusiasm over the results, stating, "This represents the first time a broad-spectrum synbiotic has been clinically shown to increase both Urolithin A and butyrate in humans. DS-01® is demonstrating measurable biological effects via the microbiome—showing the ability to positively impact gut health, inflammation levels, and potentially extend healthy aging."

About Seed Health

Founded to leverage the full potential of the microbiome, Seed Health is dedicated to innovating in the realms of probiotics and living medicines. Their portfolio targets health outcomes from infancy through aging, showcasing their commitment to not just human health, but also planetary wellness. The flagship brand, Seed®, is recognized for its science-first approach that prioritizes clinically validated innovations in probiotics. Seed's research also actively contributes to the restoration of ecosystems affected by human activity through initiatives like SeedLabs, which focus on biodiversity enhancement.

Conclusion

As the interest in gut health continues to rise, the implications of these findings could be transformative for both the science of the microbiome and its practical applications in health. With DS-01®, Seed Health is at the forefront of a movement that merges innovative science with tangible health benefits, potentially reshaping how we perceive and manage gut and overall health.